News Archive

By randomizing 10,000 adult patients, ARTEMIS will evaluate the effects of a study medicine versus placebo on cardiovascular outcomes in patients with acute myocardial infarction.

An antibiotic that has shown effectiveness for bacterial pneumonia also appears successful in fighting methicillin-resistant staph infections, reports a team led by Duke Health. The drug, ceftobiprole, showed similar benefit when tested against the antibiotic daptomycin to treat complicated Staphylococcus aureus bacterial infections. If approved by the FDA, ceftobiprole could provide another line of defense against a common and often deadly bacterial infection.

When it comes to COVID-19 testing and vaccination, not all Hispanic populations respond the same.

Explore how the integration of digital tools and consumer-oriented approaches in clinical trials can enhance participant diversity and recruitment efficiency while addressing challenges in equity, ethics, and security.

Cardiovascular disease is the number one killer of people in the United States and worldwide. Yet physicians often do not prescribe evidence-based medicines that could change those statistics.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no clinical benefit to taking fluticasone furoate for treatment of mild-to-moderate COVID-19 symptoms.

CardioHealth Alliance is announcing a new project sponsored by Amgen aimed at assessing and gathering data regarding how to improve quality of care among patients hospitalized for ASCVD. This work, referred to as the “Test to Treat” project, will be led by cardiovascular disease prevention specialist and DCRI faculty member Neha Pagidipati, MD, MPH.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine at a dosage of 100 mg twice daily for 13 days for the treatment of mild-to-moderate COVID-19 symptoms.

A group of promising young scientists completed the ninth annual Duke STAR Program in August, after spending the summer building research skills and working side-by-side with Duke University faculty to research medications and how they are being used.

Researchers have developed a blood test that detects Parkinson’s disease, potentially establishing a way to help diagnose the condition before nervous system damage worsens.